tetano
Editor, Senior Moderator
Clin Immunol
. 2021 Oct 4;108871.
doi: 10.1016/j.clim.2021.108871. Online ahead of print.
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
Thomas W Barnes[SUP] 1 [/SUP], Johannes Schulte-Pelkum[SUP] 2 [/SUP], Laura Steller[SUP] 2 [/SUP], Daniel Filchtinski[SUP] 2 [/SUP], Robin Jenness[SUP] 3 [/SUP], Michelle R Williams[SUP] 3 [/SUP], Christina Kober[SUP] 3 [/SUP], Sandro Manni[SUP] 1 [/SUP], Thomas Hauser[SUP] 1 [/SUP], Aaron Hahn[SUP] 4 [/SUP], Uwe Kalina[SUP] 4 [/SUP], Toby L Simon[SUP] 5 [/SUP], Patrick Schuetz[SUP] 6 [/SUP], Nathan J Roth[SUP] 1 [/SUP]
Affiliations
Abstract
Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available.
Keywords: COVID-19; Convalescent donor; Half-life; Neutralising antibodies; SARS-CoV-2.
. 2021 Oct 4;108871.
doi: 10.1016/j.clim.2021.108871. Online ahead of print.
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
Thomas W Barnes[SUP] 1 [/SUP], Johannes Schulte-Pelkum[SUP] 2 [/SUP], Laura Steller[SUP] 2 [/SUP], Daniel Filchtinski[SUP] 2 [/SUP], Robin Jenness[SUP] 3 [/SUP], Michelle R Williams[SUP] 3 [/SUP], Christina Kober[SUP] 3 [/SUP], Sandro Manni[SUP] 1 [/SUP], Thomas Hauser[SUP] 1 [/SUP], Aaron Hahn[SUP] 4 [/SUP], Uwe Kalina[SUP] 4 [/SUP], Toby L Simon[SUP] 5 [/SUP], Patrick Schuetz[SUP] 6 [/SUP], Nathan J Roth[SUP] 1 [/SUP]
Affiliations
- PMID: 34619377
- DOI: 10.1016/j.clim.2021.108871
Abstract
Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available.
Keywords: COVID-19; Convalescent donor; Half-life; Neutralising antibodies; SARS-CoV-2.